Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 ...

GOTHENBURG, SWEDEN / ACCESS Newswire / February 20, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 20 ...

C3i became the first contract development and manufacturing organization (CDMO) for cell and gene therapies in Canada to obtain a Drug Establishment License (DEL) to produce life-saving cell therapies ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli ® (pegcetacoplan) ...

The European Medicines Agency has started a review of medicines containing finasteride and dutasteride following concerns ...

Russian attackers were behind the hack of the European Medicines Agency EMA in 2020. They had “unauthorized access to ...

C3i obtained a Drug Establishment License (DEL) to produce cell therapies for patients across Canada commercially.

The global Apheresis Equipment Market is valued at $2.01 million in 2023 and is projected to reach a value of $2.20 million ...

The global Embolic Protection Devices Market is valued at $601 million in 2023 and is projected to reach $1,250 million by ...

Belgian MEP Liesbet Sommen spoke with Euractiv about critical medicines shortages, EU Pharma Package progress, and SANT's evolving role.

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has bee ...